Navigation Links
Panacea Pharmaceuticals, Inc. Presents Data That Its Cancer Biomarker HAAH is Readily Detectable in Serum Exosomes
Date:3/30/2017

GAITHERSBURG, Md., March 30, 2017 /PRNewswire/ -- Panacea Pharmaceuticals, Inc. presents a paper regarding detection of the cancer biomarker HAAH at the annual American Association for Cancer Research (AACR) meeting in Washington DC held April 1-5, 2017. The paper is titled:

"Improved Detection of Cancer Specific Serum Exosomal Aspartyl (Asparaginyl) beta Hydroxylase (HAAH)"

The paper demonstrates major refinements to Panacea's multi-cancer HAAH-exosome detection assay that targets the cancer-specific blood serum biomarker HAAH. The cancer field is intensely focused upon exosomes, which are small cell-like nanoparticles derived from the cancer cells that are proving to be important biomarkers and mediators of cancer cell metastasis and progression.

The association of Panacea's target molecule HAAH with exosomes has led to a better individual understanding of these biomarkers as well as further development of a markedly improved diagnostic test with higher sensitivity and specificity than previous versions of the assay.

"We are excited to report our continued advances in the understanding of the role of serum exosomes in the detection and monitoring of cancer," said Hossein Ghanbari, Ph.D., CEO and CSO of Panacea.

About Panacea Pharmaceuticals, Inc.

Panacea Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing novel biologically targeted cancer therapies and diagnostics for unmet medical needs and is headquartered in Gaithersburg, Md. The company has recently initiated a Phase 1 trial of its PAN-301-1 therapeutic cancer vaccine in prostate cancer patients and has late-nonclinical stage projects in serodiagnosis of cancer, immuno-imaging of cancer, monoclonal antibody-based immunotherapy of cancer and neuroprotection, specifically in prevention of chemotherapy-induced cognitive impairment and peripheral neuropathy.

Contact:  Steven Fuller, Panacea Pharmaeceuticals, Inc., 240-454-8010, sfuller@panaceapharma.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/panacea-pharmaceuticals-inc-presents-data-that-its-cancer-biomarker-haah-is-readily-detectable-in-serum-exosomes-300431997.html


'/>"/>
SOURCE Panacea Pharmaceuticals, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Goodwin Biotechnology was Selected by Panacea Pharmaceuticals for a Highly Specialized Vaccine Fill / Finish Project
2. Panacea Pharmaceuticals Engages Accelovance For Clinical Development Of Its Novel Nanoparticle-Based Therapeutic Cancer Vaccine
3. Panacea Pharmaceuticals Presents Three Papers Regarding Its Nanoparticle-Based Therapeutic Cancer Vaccine at the Society for Immunotherapy of Cancer Annual Meeting at National Harbor, MD
4. OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Year End 2016
5. Company Of Murdered California Urologist, Absorption Pharmaceuticals, Files Suit Against Multi-National Maker Of Everyday Household Products For Trade Secret Theft And Fraud
6. Provectus Biopharmaceuticals, Inc. Announces Extension of Rights Offering
7. Cornerstone Pharmaceuticals, Inc. Announces the Addition of World-Renowned Experts to Scientific and Medical Advisory Boards
8. Purcell Julie & Lefkowitz LLP Is Investigating HedgePath Pharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
9. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Anthera Pharmaceuticals, Inc. (ANTH)
10. Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
11. EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Alexion Pharmaceuticals, Inc. - ALXN
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/11/2019)... , ... June 11, 2019 , ... ... Center and Grayken Center for Addiction will help combat the opioid epidemic by ... combines two pharmacy-specific educational interventions that have shown promise in reducing opioid-related harms, ...
(Date:6/11/2019)... ... June 11, 2019 , ... Intalere, ... today announced the latest enhanced release of OptiAnalytics Navigate. This best-in-class strategic ... customers. , “We are thrilled to offer these customer-focused new features ...
(Date:6/11/2019)... ... June 11, 2019 , ... MabPlex ... Organization (CDMO) serving the global biopharmaceutical and biotechnology industries with sites in China ... the company's new Chief Executive Officer (CEO). Dr Chen will be responsible for ...
Breaking Medicine Technology:
(Date:6/13/2019)... ... June 13, 2019 , ... ... SGLT-2 Inhibitors” presented at the American Diabetes Association (ADA) Scientific Sessions 2019 involving ... being treated with an SGLT-2 inhibitor. SGLT-2 inhibitors are used to lower glucose ...
(Date:6/12/2019)... ROCHELLE, Va. (PRWEB) , ... June 12, 2019 ... ... that Andrea Miller, a quality assurance expert with more than 25 years of ... and MDD Compliance for all classes of medical devices, has joined NDA Partners ...
(Date:6/12/2019)... ... June 12, 2019 , ... Ovation Travel Group, ... today announced that its Chairman and CEO Paul Metselaar has received the Children’s ... last Wednesday evening at New York City’s Capitale as part of the Children’s ...
(Date:6/12/2019)... ... June 12, 2019 , ... Millions of people across ... from participating in education or the workforce, and even from accessing health care. ... as a human right and address communication disability in ways that foster inclusion ...
(Date:6/11/2019)... ... 11, 2019 , ... The FSH Society today announced that ... regulators, biopharma companies, and academic thought leaders to discuss the current state of ... the world’s largest research-focused patient advocacy organization for FSHD, a hereditary muscle-damaging condition ...
Breaking Medicine News(10 mins):